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Abstract. One important aspect of studies carried out at the Center for Molecular Biology “Severo Ochoa” is focused on basic
aspects of Alzheimer’s disease, mainly the search for suitable therapeutic targets for this disorder. Several groups at the Center
are involved in these studies, and, in this spotlight, the work they are carrying out will be described.
INTRODUCTION
Alzheimer’s disease (AD) is currently the most
prevalent neurodegenerative disorder in humans, af-
fecting nearly 30 million people worldwide [1]. About
1.1% of the total population of developed countries
suffer from the disease, and while no cases are found
in individuals younger than 20 years of age, there is
an incidence of about 30% in people aged 85 years or
older [2]. Thus, aging is the most important risk factor
for AD [3]. Since the average age of the population
continues to increase, the number of patients with AD
is expected to rise exponentially, and it is projected that
there will be about 110 million people affected with
the disease by 2050 [4]. Many laboratories around the
world are looking for the means to prevent this devas-
tating disease, and indeed, this is the objective of sever-
al groups working at the Center for Molecular Biology”
Severo Ochoa”.
∗Correspondence to: Jesu´s Avila, Centro de Biologı´a Molecular
“Severo Ochoa”, Nicola´s Cabrera 1, Campus de Cantoblanco UAM,
280049 Madrid, Spain. E-mail: javila@cbm.uam.es.
THE CENTER FOR MOLECULAR BIOLOGY
“SEVERO OCHOA”
The Center is a multidisciplinary Institution support-
ed by the Universidad Auto´noma of Madrid (UAM)
and the Consejo Superior de Investigaciones Cientı´ficas
(CSIC-Spanish Higher Research Council). The Center
was founded in 1975 based on the proposal of Prof.
Severo Ochoa (Nobel Prize winner) with the help of
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Prof. Federico Mayor (former Director of UNESCO)
and Prof. Eladio Vin˜uela. The Center was officially
opened by the King and Queen of Spain and initial-
ly contained four departments headed by Drs. Mayor,
Vin˜uela/Salas, Vazquez, and Garcı´a Bellido. One of
these, the Neurochemistry Department, was the precur-
sor of our actual Department of Neurosciences. Since
then, the research areas at the Center have expanded
to incorporate groups working in several other fields
such as developmental biology, virology, immunology,
molecular microbiology, cell biology, and the regula-
tion of gene expression. In addition, the center now of-
fers a range of scientific services and shared facilitates
to support the day-to-day research activities.
The groups that belong to the Department of Neuro-
chemistry are working on many different areas of cell
and molecular neurobiology, involving studies into neu-
rotransmitters, transporters, neural stem cells, neuron
aging, neuron repair, or neurological signaling. In ad-
dition, a large number of groups in the Department are
working on neurodegeneration, spinocerebellar ataxi-
as, Huntington’s disease, and AD.
In this article, we shall focus on the work carried out
by the different groups that focus on distinct aspects of
AD.
IDENTIFICATION OF ALZHEIMER’S
DISEASE GENES BY FUNCTIONAL
GENOMICS
M.J. Bullido/F. Valdivieso
Summary
This group has developed neuronal cell models of
human pathogenic processes in order to search for nov-
el markers and therapeutic targets for the genetic and
sporadic forms of AD. Gene expression and gene si-
lencing studies are carried out in models, as well as
genetic association studies in case control samples that
are obtained through a close collaboration with clinical
researchers at the University Hospital “la Paz”. The
group is part of research networks like the CIBERNED
and the recently created Biomedical Research Institute
of “la Paz” Hospital (IDIPAZ). While the models have
been developed independently from other groups, like
the genomic and gene silencing experiments, the ge-
netic association studies are made possible by an inter-
action with the clinical group, which is reinforced by
collaborative projects within the CIBERNED network.
For the past few years, the group’s work has focused
on mouse models of infection with herpes simplex virus
1 (HSV1), in which the involvement of APOE in HSV1
neuro-invasiveness was described,as well as the latency
and maternal transmission to the progeny [5–8]. In
addition, a genetic association of sporadic AD with
genes relevant to HSV1 infection in humans (TAP2,
EIF2AK2, GNB3/ADRB1) was also reported [9–11].
Human neuronal cell models of oxidative stress, en-
doplasmic reticulum stress, amyloid-β protein precur-
sor (AβPP) mutations, and HSV1 infection have been
developed and their analyses with genomic tools is un-
derway.
The group’s most recent findings include: the
demonstration that oxidative stress specifically mod-
ulates cholesterol metabolism in neuroblastoma cells;
that the silencing of HMGCR, a key enzyme in choles-
terol biosynthesis, inhibits the oxidative stress-induced
apoptosis; and that HMGCR is genetically associated
with sporadic AD [12]. In conjunction, these data re-
veal a connection between oxidative stress, cholesterol,
and apoptosis in the pathogenesis of AD. Further anal-
yses of this model has shown that oxidative stress influ-
ences the metabolism/processing of AβPP, modulating
the production of the amino terminal proteolytic frag-
ments (soluble extracellular AβPP), and of the intra-
cellular carboxyl terminal αCTF (non-amyloidogenic)
and βCTF (amyloidogenic) fragments.
In the cell models of familial AD (neuroblastoma
cells stably expressing “wild type” or mutant AβPP),
it has been possible to show that mutations sensitize
the cells to the damage induced by oxidative stress, and
that the AβPP processing induced by oxidative stress
depends on the form of AβPP carried by the cells (“wild
type” or mutant).
Regarding the neuronal cell model of viral infection,
this group found that HSV1 induces an accumulation
of autophagic vesicles in the later stages of infection,
due to a defect in the fusion of these vesicles with lyso-
somes. The defect in autophagic degradation, togeth-
er with the inhibition of Aβ peptide secretion and the
increase of γ-secretase activity also induced by HSV1,
produces a marked accumulation of intracellular Aβ
in the autophagic vesicles of infected cells. Moreover,
the effects of HSV1 on autophagy and on AβPP pro-
cessing are exacerbated in the presence of oxidative
stress. In conclusion, HSV1 can produce the character-
istic pathological hallmarks of AD neurodegeneration
and indeed, the deregulation of both processes induced
by HSV1 could contribute to the accumulation of Aβ
characteristic of AD.
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Fig. 1. Confocal and electronic micrographs of HSV1 infected neuroblastoma cells, illustrating the onset of autophagy in the infected cells (upper
panel, co-localization of HSV1 with LC3; lower panel, multimembrane autophagic vesicles).
In addition, this group is also involved in collab-
orative genetic association studies, like the European
Consortium that has reported one of the biggest AD
genome-wide association study (GWAS) performed to
date [13]. Moreover, the group continues to consoli-
date its collaboration with other groups participating in
CIBERNED that are active in this area, collaborations
that are proving to be very interesting and fruitful [14–
16].
In the near future, the goal of this group is to focus
on the genomic analysis of the cell models of AβPP
mutations and HSV1 infection, together with studies
in humans: genetic association and “in situ” searches
for infectious agents, mainly using samples provided
by Spanish Brain Banks associated to CIBERNED.
Collaborations in Spain
The group collaborate with others involved in the
search of AD susceptibility genes, like Drs. Ana Frank
(Hospital “la Paz”. Madrid), Elisabet Vilella and Mar-
cel Rosich (University Rovira i Virgili and Hospital
Pere Mata. Reus), Onofre Combarros (Hospital “Mar-
que´s de Valdecilla”. Santander), Jordi Clarimo´n (Hos-
pital “Sant Pau”. Barcelona), Eva Carro (Hospital “12
de Octubre”. Madrid), Miguel Calero (ISCIII. Madrid)
and Pau Pastor (CIMA. Navarra), and also with Drs
Isidro Ferrer (Human Brain Bank, Neuropathology In-
stitutute of the Bellvitge Hospital, Barcelona) and Al-
berto Ra´bano (Human Brain Bank, Fundacion CIEN,
Madrid).
Collaboration in Europe
European Consortium for Alzheimer’s Genetic Re-
search. Coordinated by the Institut Pasteur de Lille (JC
Lambert/P Amouyel).
Educational activities
– Professors Valdivieso and Bullido are regularly in-
volved in University teaching activities,giving lec-
tures on the graduate and post-graduate (Master)
courses in Biochemistry and Molecular Biology.
– They also lectures in specialist courses in the fields
of genomics and neurodegenerative diseases (10-
15 lectures/year).
– They participate in graduate and master’s practical
classes (1/2 students per academic year).
– In the last five years, the group has presented eight
doctoral theses.
GSK3 AND ALZHEIMER’S DISEASE
F. Hernandez
Glycogen synthase kinase 3 (GSK3) is a protein ki-
nase for which two isoforms exist, GSK3α and GSK3β.
Deregulation of neuronal GSK3 activity has been pos-
tulated as a key feature in AD, mainly because GSK3
(mainly GSK3β) interacts with many of the cellular
components associated with AD neuropathology, such
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as AβPP, presenilins, and the tau protein (the main
component of neurofibrillary tangles) [17]. A trans-
genic mouse with forebrain overexpression of GSK3β
(GSK3 mice) has been generated, and it recapitulates
many aspects of AD neuropathology, such as tau hy-
perphosphorylation, reactive astrocytosis, and neuronal
death [18], as well as spatial learning deficit [19]. Since
transgene expression in these GSK3 mice is conditional
using the Tet-off system, it is possible to test whether
the biochemical, histopathological, and behavioral con-
sequences of elevated GSK-3 expression can be revert-
ed when normal GSK-3 activity is restored (as an ideal
inhibitor might do). In fact, shutdown of GSK3 overex-
pression led to normal GSK3 activity, normal phospho-
tau levels, diminished neuronal death, and suppression
of the cognitive deficit, further supporting the potential
use of GSK3 inhibitors in the treatment of AD [20].
To further study the involvement of GSK3 in AD,
transgenic mice that overexpress GSK3β and FTDP-17
tau have been crossed [21]. The CA1 hippocampalneu-
rons in this AD animal model, termed GSK3/VLW, ac-
cumulate hyperphosphorylated tau in the region where
the pattern of expression of both transgenes overlaps.
Tau filaments with a paired helical filament (PHF)-
like structure were found in GSK3/VLW mice but not
in single transgenic mice expressing only GSK3β or
FTDP-17 tau, and the formation of PHF-like filaments
in GSK3/VLW mice was accompanied by thioflavin-S
staining. All these data suggest that there is a syner-
gistic contribution of both types of tau modification,
hyperphosphorylation and missense mutations, that in-
duces aberrant tau aggregation. This animal model has
been used to study the effects of lithium, a GSK3 in-
hibitor used to treat affective disorders and with well
documented effects in humans [22]. In this model, two
questions were assessed: first, whether chronic lithium
treatment prevents the formation of the aberrant tau ag-
gregates generated by overexpression of FTDP-17 tau
and GSK3β; and second, whether lithium can return
the tau aggregates and neurofibrillary tangles generat-
ed to their former state in aged animals. The results
indicated that lithium could prevent the development
of the tau pathology when administered early in dis-
ease progression. Also, even when administered at lat-
er stages of the disease, lithium was able to reduce tau
hyperphosphorylation although it could not reverse tau
aggregation. These data offer encouragement to car-
ry out studies based on novel GSK3 inhibitors as new
pharmacological treatments of these kinds of neurode-
generative disorders [23].
A characteristic of the transgenic models overex-
pressing GSK3 is a reduced and atrophied dentate
Fig. 2. Altered calcium homeostasis in AD may contribute to the
physiological, and eventually to the neuropathological activation of
the calpain/GSK3/CDK5 pathway, and to tau hyperphosphorylation.
gyrus [21]. In collaboration with Dr. Verdugo (Va-
lencia, Spain), it was recently demonstrated that these
alterations might be due to a failure of the proliferation
and maturation of stem cells in the adult dentate gyrus,
which represents a novel view of AD progression [24].
Thus, GSK3β overexpression not only produces a re-
duction in adult neural stem cells in the sub-granular
zone, but also in their proliferative capacity. Trans-
genic mice develop fewer neurogenic niches and there
is less proliferation in these niches, leading to their al-
most complete depletion with age, phenomena which
could play a role AD in humans.
During these studies with animal models, additional
bands of lower apparent molecular weight were consis-
tently found in overexposed immunoblots probed with
some anti-GSK3 antibodies, suggesting the presence
of specific proteolytic fragments. The effects of some
proteases were examined and the involvement of cal-
pain in cleaving GSK3 was demonstrated [25]. More-
over, it was shown that GSK3β is truncated by calpain
in vitro, while GSK3α is not such a good substrate.
The N-terminus of the kinase is the region cleaved by
calpain and this cleavage of GSK3 was shown to take
place in cortical neurons after glutamatergic stimula-
tion. Interestingly, memantine, a non-competitive NM-
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DA receptor that has been approved for the treatment
of moderate to severe AD, can inhibit the truncation of
GSK3 induced by NMDA in primary cultures of cor-
tical neurons in a dose-dependent manner [26]. To-
gether, these data demonstrate a new means of regulat-
ing GSK3 (Fig. 2) with important implications for its
physiological and pathological activity.
In the last five years (2006–2010), the work carried
out by this group has given rise to three theses and thirty
eight scientific manuscripts. The group has received
grants from the Fundacio´n La Caixa, Comunidad de
Madrid, and Fundacio´n CIEN.
MOLECULAR MECHANISM OF
NEURODEGENERATION AND
REGENERATION
F. Wandosell/JJ Garrido
Summary
The efforts of this group are devoted to the analysis
of the molecular mechanisms triggered by neurodegen-
erative processes. The aim of these studies is to de-
termine the key signals that regulate cell morphogen-
esis and how the pathways they modulate are affected
in pathological situations such as AD or ischemia. In
addition, possible regenerative mechanisms are inves-
tigated.
Analyzing cell and animal models of neurodegen-
eration, it has been possible to show that increases in
GSK3 activity correlate with neuronal degeneration,
and in some cases with neuronal death. In some of
these models, the PI3K-Akt-GSK3 pathway was seen
to be deregulated, which was at least in part responsible
for the process of neurodegeneration. The group is now
deeply committed to understanding how the activity of
GSK3 is regulated. Complementing these studies are
the efforts to try to determine the role of some neu-
roprotective hormones, such as estradiol. Recent data
demonstrates that estradiol inhibits GSK3 in a similar
fashion to IGF-1 [27,28]. Hence, it is important to iden-
tify elements implicated in this neuroprotection, and to
address whether the activation of “hormonal neuropro-
tection” may influence the progress of AD or ischemia
in the models available.
In addition efforts are being made to understand the
key signals that regulate neuronal morphogenesis, par-
ticularly having demonstrated that GSK3 is essential
to determine, and to maintain, certain properties of ax-
ons in models of axonal polarity. More elements are
Fig. 3. The scheme represents a summary of the recent results from
this group (bold red lines and red letters), indicating a new pathway in
which β-catenin may be regulated by either the Wnt pathway and/or
estradiol signaling.
now being analyzed, either upstream or downstream of
GSK3, as key cues in axonogenesis. Thus, the aim is
to more fully define this cellular compartment, which
is critical to neuronal function.
Collaborations in Spain
– Collaboration with Dr. I Anton (CNB, Madrid),
“Role of actin binding protein in neuronal mor-
phogenesis”.
– Collaboration with Dr. J.M. Torres (CISA, Madrid)
and Dr. A. del Rio (UB, Barcelona) on prion neu-
rodegeneration.
– R& D Collaboration agreement with FAES FAR-
MA and NOSCIRA.
Collaborations in Europe
Seventh Framework Program NMP: Nanosciences,
Nanotechnologies,Materials and new Production Tech-
nologies: “Nanoparticles for Therapy and Diagnosis
of Alzheimer’s Disease”- (NAD). Grant ref: CP-IP
212043-2 NAD.
Educational activities
– Masters in “Molecular Biomedicine”, Unv. Au-
tonoma Madrid-(UAM, BMM6)- Coord. Dr. J.
Dı´az-Nido and Dr. F. Wandosell.
– Masters in “Cell and Molecular Biology”, Unv.
Autonoma Madrid-(UAM, BM9) Coord.- Dr. I.
Anto´n and Dr. M. Cervera.
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CONDITIONAL MOUSE MODELS TO STUDY
CENTRAL NERVOUS SYSTEM DISORDERS
J.J. Lucas
Dr. Jose J. Lucas and his research team focus their
efforts on the generation and characterization of trans-
genic mouse lines to study neurodegenerative diseases
and other central nervous system conditions. Dr. Lu-
cas was a pioneer in generating conditional transgenic
mouse models to explore the reversibility of neurode-
generative diseases. The inducible mouse model of
Huntington’s disease was the first example of such an
approach, and with which the reversibility of the neu-
rological phenotype of the disease was demonstrated
through the in vivo clearance of the characteristic in-
traneuronal inclusion bodies [29]. Such reversal al-
so takes place in advanced stages of the disease when
the mice have already experienced significant loss of
striatal neurons [30]. These results provided the proof
of concept for the currently ongoing initiatives of mu-
tant huntingtin silencing as a therapeutic strategy for
Huntington’s disease and other poly-glutamine disor-
ders [31].
Transgenic mice that conditionally express GSK3
have been generated in collaboration with Drs. Avi-
la and Herna´ndez. Given the aforementioned implica-
tions of GSK3 in the etiology of AD, these mice are
considered to be an interesting mouse model of AD
that recapitulates tau hyperphosphorylation and neu-
ronal death [18], as well as the learning deficits associ-
ated with AD [19]. These mice are also a useful tool to
assay the therapeutic potential of GSK3 inhibitors and
due to the conditional design, it could be used to show
that the phenotype produced by excess GSK3 activity
is susceptible to reversion when normal GSK3 activity
is restored [20].
More recently, mice with conditional and neuronal
expression of a dominant negative form of GSK3 (DN-
GSK3) have been generated as a tool to predict the
neurological consequences of sustained GSK3 inhibi-
tion, either per se or in combination with mouse mod-
els of disease. These mice suffer increased apoptosis
in certain brain regions such as the striatum [32] and
accordingly, also develop subtle motor abnormalities.
This data might predict unwanted side-effects of chron-
ic treatment with GSK3 inhibitors. Fortunately, both
the levels of apoptosis and the deficit in motor perfor-
mance returned to normal upon restoring basal GSK3
activity secondary to transgene silencing [32].
Lithium is a GSK3 inhibitor that is the mainstay for
treatment and prophylaxis of bipolar disorder. This
compound has also been proposed as a treatment for AD
and other neurodegenerative diseases [33], although
clinical trials are hampered by lithium’s prominent
side-effects in the elderly [34]. Since the neurological
side-effects of lithium frequently include motor signs
such as tremor [35], the similarities with the phenotype
of the DN-GSK3 mice led Drs. Raquel Go´mez-Sintes
and Lucas to hypothesize that therapeutic levels of lithi-
um could also induce neuronal loss through GSK3 in-
hibition. In fact, they found an induction of neuronal
apoptosis in various brain regions associated with the
motor deficits in mice treated chronically with lithi-
um [36]. They also found that GSK3 inhibition aug-
mented the translocation of nuclear factor of activated
T cells c3/4 (NFATc3/4) transcription factors to the nu-
cleus, leading to increased Fas ligand (FasL) expres-
sion and Fas activation. Lithium-induced apoptosis and
motor deficits were absent when nuclear translocation
of NFAT was prevented by cyclosporin-A administra-
tion and in Fas-deficient lpr mice [36]. These results
provide evidence of the mechanism by which lithium-
induced neuronal and motor toxicity. Moreover, these
findings may enable the development of combined ther-
apies that diminish the toxicity of lithium and possibly
of other GSK3 inhibitors, extending their potential to
treat AD and other neurodegenerative conditions.
The laboratory of Dr. Lucas has also explored the po-
tential contribution of the ubiquitin proteasome system
(UPS) in the pathogenesis of neurodegenerative disor-
ders, with special emphasis on Huntington’s disease.
The experimental approaches employed range from the
analysis of the endoproteolytic activities of the pro-
teasome in vitro [37,38], or in homogenates from cell
and mouse models [39,40], to the use of UPS-reporter
transgenic mice [41,42].
SYNAPTIC SIGNALING IN ALZHEIMER’S
DISEASE AND THERAPEUTIC
OPPORTUNITIES
J. A. Esteban
Summary
AD is a neurodegenerative disorder in which pro-
gressive memory loss is accompanied by cognitive de-
cline. AD is of special interest to neuroscientists not
only because it is the most common cause of demen-
tia in adults but also because it usually begins with a
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remarkably genuine impairment of cognitive function.
Despite intensive research, the mechanisms underly-
ing cognitive impairment in AD patients are still not
entirely understood. In recent years, a novel hypoth-
esis emerged that subtle alterations in synaptic func-
tion might be responsible for the cognitive deficits ob-
served in the initial stages of AD [43,44]. In fact, there
is considerable experimental evidence indicating that
Aβ alters the mechanisms underlying synaptic plastic-
ity [45,46]. Within this framework, this research group
focuses its attention on elucidating the synaptic path-
ways underlying Aβ-induced dysfunction. In addition,
efforts are made to manipulate these pathways experi-
mentally as a therapeutic approach to improve cognitive
function.
Synaptic plasticity and its relation to Alzheimer’s
disease
Synaptic plasticity is the ability of neurons to modify
their synaptic connections in response to specific pat-
terns of activation. These modifications lead to long-
lasting changes in synaptic efficacy, which are consid-
ered as the cellular basis for learning and memory [47].
Two of the best characterized forms of synaptic plastici-
ty in the hippocampus are long-term potentiation (LTP)
and long-term depression (LTD), although the precise
mechanisms responsible for these forms of synaptic
plasticity are still to be elucidated [48]. However, it
is well established that the activity-dependent trans-
port of AMPA-type glutamate receptors into and out of
excitatory synapses is a critical factor for long-lasting
changes in synaptic strength (see Fig. 4) [49].
As mentioned above, Aβ is now thought to con-
tribute to cognitive decline by interfering with synaptic
plasticity. Although the precise targets of Aβ are far
from clear, it was recently demonstrated that exposure
to Aβ oligomers leads to the removal of AMPA recep-
tors from synapses [50], as well as a shift in the bal-
ance in synaptic plasticity, impairing LTP and promot-
ing LTD (see Fig. 4) [51–53]. These results are very
exciting, since they open the possibility of targeting the
mechanisms underlying synaptic plasticity as a ther-
apeutic strategy to correct the synaptic and cognitive
dysfunction associated to AD.
Targeting the PIP3 pathway to control Aβ-induced
synaptic dysfunction
Multiple signaling pathways appear to mediate
these forms of synaptic plasticity, including the PKC,
CaMKII, MAPK, and PIP3 pathways [48]. The PIP3
signaling cascade is particularly relevant, since it is
Fig. 4. Model for AMPA receptor trafficking during synaptic plas-
ticity and the potential effects of Aβ. Calcium entry into the postsy-
naptic terminal upon NMDA receptor activation leads to the delivery
of new AMPA receptors to the synaptic membrane (LTP) or to their
removal (LTD). Aβ appears to modulate these forms of plasticity in
opposite directions, impairing LTP and enhancing LTD.
critically involved in AMPA receptor function [54]. In-
deed, deregulation of its downstream effector, GSK3β,
appears to be a key feature in AD pathogenesis (see
above).
This group has recently presented results indicating
that the equilibrium between PI3K and PTEN activity
is critical to maintain synaptic function and for the bal-
ance in synaptic plasticity, with PI3K favoring synaptic
potentiation [54] while PTEN favors synaptic depres-
sion (unpublished results). As mentioned above, it is
increasingly evident that Aβ disrupts synaptic function
by shifting the balance in plasticity towards depression.
Therefore, we believe that experimental manipulation
of the PI3K-PTEN equilibrium may serve as a ther-
apeutic approach to correct the synaptic dysfunction
associated to AD.
Current research in the laboratory is aimed at test-
ing this hypothesis in vitro and in vivo. To this end,
a multidisciplinary approach is being employed that
combines an analysis of clinical postmortem samples
from patients with AD, molecular biology and elec-
trophysiological assays on brain tissue, and behavioral
analyses of mouse models of AD following pharmaco-
logical treatment. We believe that this strategy should
help understand the basic synaptic alterations underly-
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Fig. 5. AD related effects of cholesterol loss. The figure shows one of the working models used by Dr. Ledesma’s group to explain the main
hallmarks of AD: amyloid accumulation in plaques and tau phosphorylation leading to the generation of neurofibrillary tangles and neuronal
death. Based on previous work from the laboratory, this model proposes that the moderate loss of cholesterol detected in the neuronal membrane
of AD patients will disrupt lipid raft membrane domains [55]. In turn, these rafts are responsible for the segregation of AβPP and its β-secretase,
BACE [62], and for the binding and activation of plasminogen [63]. The disorganization of rafts leads to enhanced contact between AβPP and
BACE [62], and to impaired plasmin activation, causing amyloid peptide accumulation [58]. The amyloid peptide induces the production of
tissue plasminogen activator, tPA, which in turn activates a cascade of kinases (MEK, ERK1/2, GSK3) leading to tau hyperphosphorylation and
neuronal death [63].
ing AD, and at the same time, provide information to
advance towards developing new therapeutic approach-
es to ameliorate the cognitive impairments associated
with this devastating disease.
UNDERSTANDING THE ROLE OF LIPIDS IN
ALZHEIMER’S DISEASE
M.D. Ledesma
The group led by Dr. Ledesma focuses its research on
the role that lipids may play in AD pathology. The da-
ta emanating from this and other groups have revealed
that the levels of brain cholesterol decrease and those
of sphingomyelin increase during aging, as well as in
AD patients [55–57]. The question arises as to whether
these changes are a cause or a consequence of the dis-
ease. To answer this question Dr. Ledesma’s group
uses two mouse models in which neuronal cholesterol
levels are reduced or those of sphingomyelin are in-
creased [58,59] as a result of genetic alteration of the
enzymes that control their metabolism [60,61]. These
studies aim to determine the influence of these lipid
changes on the hallmarks alterations in AD, namely: i)
amyloid peptide accumulation (i.e., AβPP processing
and plasmin-dependent amyloid degradation); ii) tau
phosphorylation; iii) synaptic alterations; iv) oxidative
stress; and v) neuronal death. The results obtained to
date point to lipid anomalies as having a causal effect in
the disease. They also make these mice a suitable ex-
perimental model to study brain aging and AD, which
will be useful for the preclinical testing of therapeutic
strategies based on lipid modulation.
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Research is also being carried out to further develop
the concepts indicated in the patent application filed
by Dr. Ledesma, together with Dr. C.G. Dotti on the
“Methods and compositions for treatment of AD by en-
hancing plasmin or plasmin-like activity” (U.S. Patent
Application Serial No. 09/502,448). This opens the
group’s activities to industrial collaborations and with
experts in the plasminogen system, such as the labora-
tory of Dr. P. Navarro (Instituto Municipal de Investi-
gaciones Medicas – IMIM, Barcelona, Spain). More-
over, the laboratory actively collaborates with groups
working on AD, lipid metabolism, or synapse function
at the KU Leuven (Belgium), such as those of Drs. C.
Bagni, P.P. Van Veldhoven, and C.G. Dotti, as well as
with groups at the University of Turin (Italy: Drs. M.
Sassoe Pogneto, M. Giustetto, and A. Vercelli). Inter-
nal collaborations with the groups working on AD and
other neurodegenerative disorders at the CBMSO are
assured through weekly meetings to discuss progress
in the area.
The group also places an important emphasis on
training and there are currently two PhD students work-
ing on the aforementioned issues. They are active in
disseminating the results through national and interna-
tional scientific congresses, and in internal and exter-
nal seminars, which adds to the group’s efforts to at-
tract and train scientists who will further develop their
research interests in AD in the future.
ALZHEIMER’S DISEASE, THE MOST
PROMINENT TAUOPATHY
J. Avila
The group of Dr. Jesu´s Avila has been working for
sometime on the possible roles of the microtubule as-
sociated protein tau in AD. In the 1980s, this group
found that tau protein can assemble in vitro forming
PHF with a similar morphology to that found in pa-
tient’s brain. As a result, several issues related to the
phosphorylation and aggregation of tau proteins have
been analyzed.
With respect to tau phosphorylation, the protein ki-
nase GSK3 was found to modify the sites identified in
phosphorylated tau isolated from the brain of AD pa-
tients and, in collaboration with the groups of Drs. Lu-
cas and Herna´ndez at our Center (see above), a trans-
genic mouse with conditional forebrain overexpression
of GSK3β was generated and characterized to analyze,
among other issues, tau phosphorylation. Other trans-
genic mice overexpressing tau were also generated and
their characterization is still ongoing. Some of these
animals can be used as potential models of the dentate
gyrus dysfunction that could take place in AD and that
results in the loss of memory in patients.
Another objective of the group is to study how the
tau pathology spreads from the hippocampal to the
cerebral cortex during AD. At the early stages of this
disease, degeneration of neurons occurs in the en-
thorhinal/hippocampal region and from there the dis-
ease spreads to the surrounding areas until it reaches
the cortex. The working hypothesis we have adopted
to study the spreading of the tau pathology in AD (and
perhaps in other tauopathies) was that after the death of
the neurons, their cytoplasmic proteins are released into
the extracellular space. Some of the proteins released
could become toxic in that milieu and the hypothesis
is that tau itself could be one such toxic extracellular
protein. The initial data that has been obtained appears
to support this hypothesis.
In several studies, Dr. Avila’s group has collaborated
with other groups in Spain, Europe, and USA. In Spain,
collaborations are maintained with the groups of Drs.
Garcı´a Verdugo, Ferrer, and Soriano. The group has
also collaborated with the group of Dr. Engel (Ireland),
and with that of Drs. Perry (Texas), Smith (Ohio), and
Vitek (North Carolina) in the USA.
Educational activities
Each week the Neurodegeneration groups hold a
seminar (the “neurodegeneration club”) to discuss the
latest developments in the field.
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